These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23685175)

  • 21. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
    Yu S; Qin D; Shangary S; Chen J; Wang G; Ding K; McEachern D; Qiu S; Nikolovska-Coleska Z; Miller R; Kang S; Yang D; Wang S
    J Med Chem; 2009 Dec; 52(24):7970-3. PubMed ID: 19928922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.
    Guo Z; Zhuang C; Zhu L; Zhang Y; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Miao Z; Zhang W
    Eur J Med Chem; 2012 Oct; 56():10-6. PubMed ID: 22940704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
    Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
    Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis of spiro-tetrahydrothiopyran-oxindoles by Michael-aldol cascade reactions: discovery of potential P53-MDM2 inhibitors with good antitumor activity.
    Wang S; Chen S; Guo Z; He S; Zhang F; Liu X; Chen W; Zhang S; Sheng C
    Org Biomol Chem; 2018 Jan; 16(4):625-634. PubMed ID: 29302672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small-molecule MDM2-p53 inhibitors: recent advances.
    Zhang B; Golding BT; Hardcastle IR
    Future Med Chem; 2015; 7(5):631-45. PubMed ID: 25921402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
    Hardcastle IR; Liu J; Valeur E; Watson A; Ahmed SU; Blackburn TJ; Bennaceur K; Clegg W; Drummond C; Endicott JA; Golding BT; Griffin RJ; Gruber J; Haggerty K; Harrington RW; Hutton C; Kemp S; Lu X; McDonnell JM; Newell DR; Noble ME; Payne SL; Revill CH; Riedinger C; Xu Q; Lunec J
    J Med Chem; 2011 Mar; 54(5):1233-43. PubMed ID: 21314128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds.
    Okaniwa M; Hirose M; Imada T; Ohashi T; Hayashi Y; Miyazaki T; Arita T; Yabuki M; Kakoi K; Kato J; Takagi T; Kawamoto T; Yao S; Sumita A; Tsutsumi S; Tottori T; Oki H; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
    J Med Chem; 2012 Apr; 55(7):3452-78. PubMed ID: 22376051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors.
    Si D; Luo H; Zhang X; Yang K; Wen H; Li W; Liu J
    Bioorg Chem; 2021 Oct; 115():105268. PubMed ID: 34426149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
    Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
    J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-κB pathway.
    Zhuang C; Miao Z; Wu Y; Guo Z; Li J; Yao J; Xing C; Sheng C; Zhang W
    J Med Chem; 2014 Feb; 57(3):567-77. PubMed ID: 24428757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
    Hardcastle IR; Ahmed SU; Atkins H; Farnie G; Golding BT; Griffin RJ; Guyenne S; Hutton C; Källblad P; Kemp SJ; Kitching MS; Newell DR; Norbedo S; Northen JS; Reid RJ; Saravanan K; Willems HM; Lunec J
    J Med Chem; 2006 Oct; 49(21):6209-21. PubMed ID: 17034127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, in vitro anticancer evaluation and in silico studies of novel imidazo[2,1-b]thiazole derivatives bearing pyrazole moieties.
    Ali AR; El-Bendary ER; Ghaly MA; Shehata IA
    Eur J Med Chem; 2014 Mar; 75():492-500. PubMed ID: 24576591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors.
    Beck HP; DeGraffenreid M; Fox B; Allen JG; Rew Y; Schneider S; Saiki AY; Yu D; Oliner JD; Salyers K; Ye Q; Olson S
    Bioorg Med Chem Lett; 2011 May; 21(9):2752-5. PubMed ID: 21123063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
    Shangary S; Wang S
    Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.
    Chessari G; Hardcastle IR; Ahn JS; Anil B; Anscombe E; Bawn RH; Bevan LD; Blackburn TJ; Buck I; Cano C; Carbain B; Castro J; Cons B; Cully SJ; Endicott JA; Fazal L; Golding BT; Griffin RJ; Haggerty K; Harnor SJ; Hearn K; Hobson S; Holvey RS; Howard S; Jennings CE; Johnson CN; Lunec J; Miller DC; Newell DR; Noble MEM; Reeks J; Revill CH; Riedinger C; St Denis JD; Tamanini E; Thomas H; Thompson NT; Vinković M; Wedge SR; Williams PA; Wilsher NE; Zhang B; Zhao Y
    J Med Chem; 2021 Apr; 64(7):4071-4088. PubMed ID: 33761253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
    Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
    Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
    Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
    J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An ultrahigh affinity d-peptide antagonist Of MDM2.
    Zhan C; Zhao L; Wei X; Wu X; Chen X; Yuan W; Lu WY; Pazgier M; Lu W
    J Med Chem; 2012 Jul; 55(13):6237-41. PubMed ID: 22694121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.